Clinical Trials on Metastatic Kidney Carcinoma

Total 40639 results

Spanish Oncology Genito-Urinary Group

Completed

Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib (Spazo-2)

Metastatic Renal Cell Carcinoma

Spain
Immatics Biotechnologies GmbH

Completed

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States, France, Romania, United Kingdom, Italy, Russian Federation, Poland, Germany, Hungary, Netherlands, Norway
National Cancer Institute (NCI)

Completed

Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer

Metastatic Renal Cell Carcinoma

United States, Peru
Peking University Cancer Hospital & Institute

Unknown

A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.

Metastatic Renal Cell Carcinoma

China
Imperial College Healthcare NHS Trust

Withdrawn

Functional Imaging in the Assessment of mRCC Response to Sunitinib

Metastatic Renal Cell Carcinoma

United Kingdom
Mendus

Completed

A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer

Metastatic Renal Cell Carcinoma

Sweden
Centro di Riferimento Oncologico - Aviano

Terminated

Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC)

Metastatic Renal Cell Carcinoma

Italy
University of Aarhus
Danish Renal Cancer Study Group

Unknown

Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer

Metastatic Renal Cell Carcinoma

Denmark
University of Chicago

Terminated

Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States
Centre Leon Berard

Completed

Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma (TORAVA)

Metastatic Renal Cell Carcinoma

France
Pfizer

Completed

Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®

Metastatic Renal Cell Carcinoma

Czech Republic
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Pfizer
Analysis Group; IMDC group

Completed

Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

Metastatic Renal Cell Carcinoma (mRCC)

Canada
Pfizer

Completed

Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting (ADONIS)

Metastatic Renal Cell Carcinoma (mRCC)

Spain, Italy, Belgium, France, United Kingdom, Austria, Greece, Netherlands
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan

Advanced or Metastatic Renal Cell Carcinoma

Japan
Pfizer

Completed

A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)

Metastatic Renal Cell Carcinoma ( mRCC)

Ecuador, Argentina, Brazil, Colombia
Radboud University Medical Center
Dutch Cancer Society

Completed

IMaging PAtients for Cancer Drug selecTion - Renal Cell Carcinoma (IMPACT-RCC) (IMPACT-RCC)

Kidney Neoplasms | Clear-cell Metastatic Renal Cell Carcinoma

Netherlands
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Renal Cell Carcinoma | Clear-cell Metastatic Renal Cell Carcinoma

United States, Canada
National Cancer Institute (NCI)

Completed

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Association Pour La Recherche des Thérapeutiques...

Completed

Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus (NEORAD)

Clear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal Carcinoma

France
Pharmacyclics LLC.

Completed

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Metastatic Renal Cell Carcinoma | Metastatic Colorectal Adenocarcinoma | Advanced Gastric Adenocarcinoma | Advanced Urothelial Carcinoma

United States, Korea, Republic of, Spain, United Kingdom
National Cancer Institute (NCI)

Completed

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

Kidney Cancer | Prostate Cancer | Bladder Cancer

United States
National Cancer Institute (NCI)

Terminated

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Novartis Pharmaceuticals

Completed

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Metastatic Renal Cell Carcinoma | Advanced Solid Tumors | Metastatic Breast Cancer

Spain, Belgium, Italy, France, United States, New Zealand, United Kingdom
Antisoma Research

Completed

Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma

Metastatic Renal Cell Carcinoma | Metastatic Malignant Melanoma

United Kingdom, New Zealand
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Multiomics Approach in Metastatic Clear Renal Cell Carcnoma

Metastatic Clear Cell Renal Carcinoma

Italy
Argos Therapeutics

Terminated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

Israel, Spain, United States, Czechia, Canada, Italy, Hungary, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Pfizer

Completed

Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line (RENACALL)

Metastatic/Advanced Renal Cell Carcinoma

France
Fox Chase Cancer Center

Terminated

Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)

Metastatic Renal Cell Carcinoma | RCC

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Terminated

Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery (TARIBO)

Clear-cell Metastatic Renal Cell Carcinoma

Italy
Roswell Park Cancer Institute
Iovance Biotherapeutics, Inc.

Withdrawn

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial Carcinoma

United States
National Cancer Institute (NCI)

Completed

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Metastatic Colorectal Cancer | Hepatocellular Carcinoma | Hepatocellular Cancer | Metastatic Pancreatic Cancer | Liver Metastasis

United States
Omar Mian

Recruiting

Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

Adenocarcinoma | Carcinoma | Metastatic Cancer

United States
Pfizer

Completed

A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

Carcinoma, Renal Cell | Clear-cell Metastatic Renal Cell Carcinoma

Turkey
Ludwig Institute for Cancer Research
Radboud University Medical Center

Completed

Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer

Metastatic Renal Cell Carcinoma

Netherlands
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (TITAN-RCC)

Carcinoma, Renal Cell | Clear-cell Metastatic Renal Cell Carcinoma

Spain, France, Italy, Germany, United Kingdom, Belgium, Czechia, Austria
Cliniques universitaires Saint-Luc- Université...

Terminated

Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy (METASUN)

Clear-cell Metastatic Renal Cell Carcinoma

Belgium
Sunnybrook Health Sciences Centre
Pfizer

Completed

Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule

Clear Cell, Metastatic Renal Cell Carcinoma

Canada
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

Metastatic Renal Cell Carcinoma (mRCC)

Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

M8891 First in Human in Solid Tumors (M8891)

Metastatic Renal Cell Carcinoma | Advanced Solid Tumors

United States
Dana-Farber Cancer Institute
Bayer

Completed

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Metastatic Renal Cell Carcinoma

United States
Leonard Appleman
Prometheus Laboratories

Completed

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

Metastatic Renal Cell Carcinoma

United States
Pfizer

Completed

Study In Patients With Kidney Cancer Treated With Sutent

Renal Cancer | Advanced or Metastatic Renal Cell Carcinoma

Slovakia
Rennes University Hospital
Ministry of Health, France

Terminated

Efficacy of Activated Lymphocytes in Renal Cell Carcinoma.

Metastatic Renal Cell Carcinoma

France
Cadex Genomics

Completed

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

Metastatic Colorectal Cancer | Metastatic Breast Cancer | Metastatic Non-Small Cell Lung Carcinoma

United States, Canada
Centre Hospitalier Universitaire de Besancon
Pfizer

Active, not recruiting

Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma (SURF)

Kidney Neoplasms | Metastatic Renal Cell Cancer

France
Andrea Harzstark
Novartis

Withdrawn

Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)

Locally Metastatic Malignant Neoplasm
Orion Biotechnology Polska Sp. z o.o.

Not yet recruiting

Study of OB-002 in Patients With Refractory Metastatic Cancer

Metastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
Medical University of South Carolina
Bristol-Myers Squibb

Withdrawn

Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma

United States

Clinical Trials on Metastatic Kidney Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations